Vivus Prescriptions

DMs Einstein

 

DMs take direction from executive management idiot.

 

What are the SE idiot? You have no clue about this drug or why the numbers started off slow. Has nothing to do with the lack of retail initially. Since retail sales flat??? Once again you are an idiot. Yes, Einstein they were flat for 2 weeks but overall since retail has launched they are up over 50%. So go read another Arena article and jump to some more ignorant conclusions.

 

It's easy to be up 50% when you start from ZERO.

 

3X that of Belviq and growing faster - despite a larger base and longer on market. Should be the other way around!! Belviq - without REMS and retail pharmacy from the start should be taking off - but it is NOT.

 

I'm just waiting for you to answer the SIMPLE question of what are the many SE???

 

Just look at IMS and Symphony's weekly numbers

 

Agreed, Belviq is a loser.

 

So much for your SE's. Just look at what is happening. Just shameful and sad.

 

Looks like you are missing your sales quota again. Rough day in the market. Hope tomorrow weekly script sales are not an indication of today's stock price.

 

Lets see ...today's weekly IMS data (yahoo finance) indicated Qsymia up 10% and Belviq 0% - FLAT. I am not shareholder - but you can not compare these products clinically. Belviq sucks.

 

You have a link to that info. I haven't been able to find it. thanks

 

Glad I left. My DM had his golden girl favorite rep conference call me with him on the line silent. What a loser. Shame on the rep for being such a kiss ass nark

 

Happens in my district too. You are so fortunate to have left. Highly unethical for both parties. Not everyone treated the same. Makes one wonder if it is encouraged by regional management to be unethical.

 

PTYou I'm still waiting for the little idiot who didn't know what he was talking about when referring to "ALL" the SE's with Qsymia. Let's see what is in the news today.......

As for Arena’s obesity treatment, Belviq, Cowen says it is staying “on the sidelines.”
“Belviq has a role in the new obesity landscape, but its efficacy is modest, and its safety profile is not without its issues,” the brokerage says.

“Our survey points to Qsymia as the obesity agent with the strongest efficacy. We also view its retail pharmacy availability and recent board changes as strong positives for Vivus,” the Cowen note said. The brokerage says it surveyed 50 obesity specialists and 50 primary care physicians and found each group identified Qsymia as the most effective treatment.

QSYMIA- MOST EFFECTIVE and STRONGEST EFFICACY
Belviq- Efficacy MODEST, SAFETY ISSUES and STAY YOUR ASS ON THE SIDELINES

GAME OVER.............THANKS FOR PLAYING!!!!!!!!!!!!!!!